{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:54:24Z","timestamp":1791428064142,"version":"4.3.3"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1001\/jamadermatol.2020.4901","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T19:15:04Z","timestamp":1609355704000},"page":"317","source":"Crossref","is-referenced-by-count":20,"title":["Brentuximab Vedotin for Relapsed or Refractory S\u00e9zary Syndrome"],"prefix":"10.1001","volume":"157","author":[{"given":"Daniel J.","family":"Lewis","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Haun","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Samimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela C.","family":"Vittorio","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Villasenor-Park","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Department of Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Department of Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Department of Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Department of Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Department of Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"dbr200019r1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"dbr200019r2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study.","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"29","key":"dbr200019r3","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"dbr200019r4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy.","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"10094","key":"dbr200019r5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"32","key":"dbr200019r6","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase ii trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis.","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"dbr200019r7","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project.","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"dbr200019r8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jamadermatol.2017.3593","article-title":"Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of phase 2 results.","volume":"153","author":"Lewis","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"dbr200019r9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamadermatol.2013.5741","article-title":"A case of refractory S\u00e9zary syndrome with large-cell transformation responsive to brentuximab vedotin.","volume":"150","author":"Corey","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dbr200019r10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jamadermatol.2014.1629","article-title":"Brentuximab as a treatment for CD30+ mycosis fungoides and S\u00e9zary syndrome.","volume":"151","author":"Mehra","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"dbr200019r11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.2015.172.issue-3","article-title":"Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.","volume":"172","author":"Saintes","year":"2015","journal-title":"Br J Dermatol"},{"key":"dbr200019r12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC Cutaneous Lymphoma Task Force.","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"issue":"32","key":"dbr200019r13","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model.","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"dbr200019r14","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"dbr200019r15","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides.","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2774504\/jamadermatology_lewis_2020_br_200019_1615934569.39372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T15:02:38Z","timestamp":1615993358000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2774504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.4901","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}